-10%

est. 2Y upside i

HealthcareSeries B

Enabling better self care with at-home hormone tracking.

Rank

#1402

Sector

HealthTech / MedTech / Healthcare

Est. Liquidity

~3Y

Data Quality

Data: Medium

Inito, a profitable HealthTech company with ~$8M revenue, recently secured $29M in Series B funding, implying an estimated valuation of $120M.

Last updated: March 10, 2026

Bull (24%)+250%

Inito successfully leverages its AI-engineered antibodies and 'Flat-lens' technology to rapidly expand into broader at-home hormone and health diagnostics, capturing significant market share from traditional lab testing. Revenue grows to over $60M by 2028, justifying a $420M+ valuation at a premium multiple, driven by strong product adoption and recurring consumable sales.

Base (43%)+75%

Inito maintains its strong position in fertility monitoring while making steady progress in expanding its broader diagnostics platform. It continues to grow revenue at a healthy pace, reaching approximately $25M by 2028, and achieves a valuation of around $210M, reflecting solid execution in a competitive market.

Bear (33%)-70%

Increased competition from established healthcare incumbents and larger tech companies, coupled with slower-than-expected adoption of new diagnostic tests, stifles Inito's growth. Revenue stalls, leading to a down round or acquisition at a valuation of $36M or less, resulting in a significant loss for common stock holders due to the $45M in liquidation preferences.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Investors hold $45M in liquidation preferences, meaning common stock holders would only see returns after this amount is paid out, significantly impacting returns in exits at or below the current $120M valuation.

Dilution Risk

moderate

As a Series B company, Inito will likely require at least one more significant funding round (Series C) before a liquidity event, leading to further dilution for existing equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Inito's shares at this stage.

Questions to Ask at the Interview

Strategic questions based on Inito's data — designed to show you've done your homework.

  • 1

    “Given the 'medium' incumbent threat and the entry of larger tech companies into broader at-home diagnostics, how is Inito strategically positioning its AI-engineered antibodies and 'Flat-lens' technology to differentiate and defend its market share against these well-resourced players?”

  • 2

    “With current revenue at ~$8M and a composite TAM of $9.5B, what are the key milestones and growth levers Inito plans to pull over the next 24 months to significantly scale its revenue, particularly in the broader at-home hormone and health diagnostics segment, and what specific revenue targets are you aiming for?”

  • 3

    “Considering the $45M in total funding and the recent Series B, how does Inito envision the path to a liquidity event (e.g., IPO or acquisition) within the next 2-4 years, and what are the company's plans for managing potential future dilution for employees holding common stock or options?”

Community

Valuation Sentiment

Our model estimates -10% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.